close

AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.62
-1.52 (-0.64%)
AAPL  288.70
+6.96 (2.47%)
AMD  580.78
+41.29 (7.65%)
BAC  56.98
-0.91 (-1.56%)
GOOG  353.52
+2.24 (0.64%)
META  560.73
-1.87 (-0.33%)
MSFT  371.16
+2.59 (0.70%)
NVDA  199.13
+4.16 (2.14%)
ORCL  146.77
-0.99 (-0.67%)
TSLA  418.85
+7.01 (1.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today